Vericel stock
VCELNASDAQVericel Corporation, HealthcareISIN US92346J1088
66Score 66 out of 100, Neutral
Price and trend
80 / 100
Price history
+42% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 46% above it.
Since June 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 76).
The price is 3.4% below its 52-week high. Largest decline in 20 years: 99% (January 2007 to November 2015).
Chart figures for advanced users
- SMA 50$42.45
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$39.30
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)76
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$29.34
- The lowest closing price of the last twelve months.
- Resistance$59.45
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Vericel Corporation belongs to the Biotechnology industry (United States) and, with a market value of $2.93B, is number 102 of 296 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $276.26M (up 16.5% year on year) and earnings of $16.52M (up 59.4%).
- For fiscal 2026, analysts expect on average revenue of $336.25M (up 21.7%) and adjusted earnings per share of $0.54 (up 72.6%).
Show more
- MEQIRI Score 66 out of 100 (Neutral): rank 208 of 714 in Healthcare, median 53.
- The P/E is 91.3 (Biotechnology median 21.3, own median of recent years 109.1).
- Our model puts fair value at $28.19, with the price 111% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 39.1% a year since 2020.Growth 95
- Analysts expect strong earnings growthUp 39.9% a year through 2028 (estimates from 7 analysts).Growth 95
- More cash than debtCash $170.27M, financial debt $91.15M.Stability 78
Weaknesses
- Above fair valuePrice 111% above the fair value of $28.19.Valuation 17
- DilutionShare count up 12% since 2020.Capital allocation 34
Its standout strengths are momentum and growth, while capital allocation and valuation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- high price swings
- high growth grade (crashed more often in the backtest)
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly overvaluedClosing price of 11 Nov 2026, used by the daily score.
In our model the price counts as cheap below $20.14 and expensive above $46.99 (uncertainty high, based on the price swings of the past year).
The two parts of the fair value come to $43.00 (cash-flow model) and $13.39 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is above both.
Calculated with a cost of equity of 9.4%. At 10.4% the fair value would be $24.67, at 8.4% it would be $33.29.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (21.3).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 25.3% on the twelve months before. Revenue has grown strongly since 2005, at around 35% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 74%, operating 4%, net 6%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with low debt and comfortable interest coverage.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $0.27 (expected $0.06)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $0.540.0%
- Revenue
- $336.25M0.0%
- Earnings per share
- $0.87+0.2%
- Revenue
- $392.97M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −9.0%2026 total revenue guidance raised by $10 million to $326 million to $336 million, Burn Care revenue raised to $44 million to $48 million (from $36 million to $40 million).
“We now expect full year Burn Care revenue of approximately $44 million to $48 million compared to our prior guidance of $36 million to $40 million. And for the second quarter, we expect approximately $9 million to $10 million of total Burn Care revenue.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 7 insiders sold, $7.24M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Mara Joseph Anthony JrSale
6 Nov 2026, Chief Financial Officer
- Shares
- 28,641
- Price
- $53.42
- Value
- $1.53M
- Mara Joseph Anthony JrSale
5 Nov 2026, Chief Financial Officer
- Shares
- 21,359
- Price
- $53.56
- Value
- $1.14M
- Siegal JonathanSale
5 Nov 2026, Principal Accounting Officer
- Shares
- 1,500
- Price
- $52.90
- Value
- $79,350
Show 14 more
- Flynn Sean C.Sale
5 Nov 2026, Chief Legal Officer
- Shares
- 15,000
- Price
- $51.92
- Value
- $778,800
- Zerbe Robert L MdSale
5 Nov 2026, Board
- Shares
- 3,000
- Price
- $52.23
- Value
- $156,675
- Zerbe Robert L MdSale
4 Nov 2026, Board
- Shares
- 2,500
- Price
- $45.40
- Value
- $113,500
- Mclaughlin Kevin FSale
12 Aug 2026, Board
- Shares
- 7,000
- Price
- $44.53
- Value
- $311,710
- Halpin MichaelSale
3 Aug 2026, Chief Operating Officer
- Shares
- 10,000
- Price
- $46.84
- Value
- $468,400
- Siegal JonathanSale
30 Jul 2026, Principal Accounting Officer
- Shares
- 500
- Price
- $48.90
- Value
- $24,450
- Siegal JonathanSale
26 Jun 2026, Principal Accounting Officer
- Shares
- 2,500
- Price
- $44.90
- Value
- $112,250
- Mara Joseph Anthony JrSale
26 Jun 2026, Chief Financial Officer
- Shares
- 5,000
- Price
- $44.75
- Value
- $223,750
- Hopper Jonathan MarkSale
26 Jun 2026, Chief Medical Officer
- Shares
- 5,000
- Price
- $45.00
- Value
- $225,000
- Flynn Sean C.Sale
26 Jun 2026, Chief Legal Officer
- Shares
- 15,000
- Price
- $45.64
- Value
- $684,600
- Halpin MichaelSale
18 Jun 2026, Chief Operating Officer
- Shares
- 10,000
- Price
- $40.24
- Value
- $402,400
- Flynn Sean C.Sale
18 Jun 2026, Chief Legal Officer
- Shares
- 15,000
- Price
- $40.21
- Value
- $603,150
- Hopper Jonathan MarkSale
2 Jun 2026, Chief Medical Officer
- Shares
- 4,375
- Price
- $35.00
- Value
- $153,125
- Mclaughlin Kevin FSale
13 May 2026, Board
- Shares
- 7,000
- Price
- $32.83
- Value
- $229,775
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Vericel
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 66
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- Disc MedicineIRON $3.34B42
- Telix PharmaceuticalsTLX $3.23B40
- Acadia PharmaceuticalsACAD $3.17B62
- IDEAYA BiosciencesIDYA $3.16B39
- Xeris Biopharma HoldingsXERS $3.02B56
- XencorXNCR $3B46
- Zai LabZLAB $2.98B49
- ADMA BiologicsADMA $2.93B71
ETFs that hold Vericel
Held by 13 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.25% | 0.40% | €807M |
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.17% | 0.35% | €1.21B |
| iShares S&P SmallCap 600 UCITS ETFIUS3 | 0.13% | 0.30% | €2.28B |
Show 5 more
| L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ | 0.12% | 0.30% | €185.82M |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.10% | 0.30% | €4.22B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.01% | 0.43% | €2.48B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 3 Apr 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.